Anna-Maria Hoffmann-Vold,Oliver Distler,Cosimo Bruni et al.
Anna-Maria Hoffmann-Vold et al.
The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related...
[This corrects the article DOI: 10.1016/S2665-9913(21)00248-4.]. © 2022 Elsevier Ltd. All rights reserved.
Published Erratum
The Lancet. Rheumatology. 2022 Aug;4(8):e530. DOI:10.1016/S2665-9913(22)00194-1 2022
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City [0.03%]
纽约市系统性红斑狼疮患者初始接种新冠疫苗系列及加强针后的突破性SARS-CoV-2感染、疾病负担和血清学反应
Amit Saxena,Alexis J Engel,Brittany Banbury et al.
Amit Saxena et al.
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform [0.03%]
英国开放安全平台有关自身免疫性炎症性疾病和免疫调节疗法的严重新冠肺炎预后的队列研究
Brian MacKenna,Nicholas A Kennedy,Amir Mehrkar et al.
Brian MacKenna et al.
Background: The risk of severe COVID-19 outcomes in people with immune-mediated inflammatory diseases and on immune-modifying drugs might not be fully mediated by comorbidities and might vary by factors such as ethnicity....
Philip C Robinson,Jinoos Yazdany
Philip C Robinson
Alfred H J Kim,Jeffrey A Sparks
Alfred H J Kim
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies [0.03%]
免疫抑制剂治疗的自身免疫性疾病的患者感染Delta（B.1.617.2）变异株新冠肺炎：两项前瞻性队列研究中的一个子课题研究报告
Laura Boekel,Eileen W Stalman,Luuk Wieske et al.
Laura Boekel et al.
Background: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with immunosuppressants, but clinical data on break...
Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis [0.03%]
硫唑嘌呤剂量对系统性硬化症患者初始新冠疫苗接种后抗体反应的影响
Rachel Wallwork,Caoilfhionn M Connolly,Matthew Shneyderman et al.
Rachel Wallwork et al.
Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases [0.03%]
自身免疫性炎症性疾病患者的新冠疫苗效力
Jeffrey A Sparks,Namrata Singh,Zachary S Wallace
Jeffrey A Sparks
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis [0.03%]
2021年3月22日至11月22日在加拿大安大略省进行的自身免疫性炎症性疾病患者SARS-CoV-2感染和严重病情的疫苗有效性：基于人口的分析
Jessica Widdifield,Jeffrey C Kwong,Simon Chen et al.
Jessica Widdifield et al.
Background: We estimated COVID-19 vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes among individuals with immune-mediated inflammatory diseases in Ontario, Canada. ...